Prelude Therapeutics (PRLD) Asset Utilization Ratio (2025 - 2026)

Prelude Therapeutics (PRLD) posted Asset Utilization Ratio of 0.13 for Q1 2026, down 6.29% sequentially from 0.14 in Q4 2025.

Analysis

Prelude Therapeutics (PRLD) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

Prelude Therapeutics has reported Asset Utilization Ratio for 2 years, with the latest figure at 0.13 in Q1 2026.

Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.13 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.13 (changed N/A YoY) and the FY2025 annual result came in at 0.08, up 148.06% from the prior year.
Asset Utilization Ratio slipped to 0.13 in Q1 2026 per PRLD's latest filing, from 0.14 in the prior quarter.
Over five years, Asset Utilization Ratio peaked at 0.14 in Q4 2025 and troughed at 0.13 in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	0.47
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	0.38
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	0.20
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	0.69
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	0.90
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.13
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	0.54
10	Prelude Therapeutics	539.17 Mn	258.54 Mn	-	0.15

Historic Data

Download Data